PIK3CA Mutation Status as a Biomarker in Elderly Women With Breast Cancer
- To validate PIK3CA mutation status as a biomarker in women 70 years or older diagnosed
with breast cancer.
OUTLINE: Genomic DNA extracted from archived tumor tissue samples are analyzed for mutation
by Sequenom multiplex massARRAY (multiplex PCR and mass spectroscopy). Results are then
analyzed by massARRAY TyperAnalyzer v4.0 software. Patients clinical data are also analyzed,
including treatment received.
Breast cancer-free interval of patients with PIK3CA-mutated tumors as compared to wild-type tumors
Mary Ellen Moynahan, MD
Memorial Sloan-Kettering Cancer Center